vs
AstroNova, Inc.（ALOT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
AstroNova, Inc.的季度营收约是REGENXBIO Inc.的1.3倍（$39.2M vs $30.3M），AstroNova, Inc.净利率更高（1.0% vs -221.3%，领先222.3%），REGENXBIO Inc.同比增速更快（43.0% vs -3.4%），AstroNova, Inc.自由现金流更多（$3.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 2.1%）
AstroNova是一家全球化科技企业，主打专业数据可视化产品与解决方案，核心产品包括高性能标签打印机、测试测量设备、航空级数据记录系统，服务航空航天、工业制造、零售、医疗等多个领域，客户遍及全球主要市场。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ALOT vs RGNX — 直观对比
营收规模更大
ALOT
是对方的1.3倍
$30.3M
营收增速更快
RGNX
高出46.4%
-3.4%
净利率更高
ALOT
高出222.3%
-221.3%
自由现金流更多
ALOT
多$56.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
2.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.2M | $30.3M |
| 净利润 | $378.0K | $-67.1M |
| 毛利率 | 36.2% | — |
| 营业利润率 | 3.3% | -190.0% |
| 净利率 | 1.0% | -221.3% |
| 营收同比 | -3.4% | 43.0% |
| 净利润同比 | 221.5% | -31.2% |
| 每股收益（稀释后） | $0.05 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALOTRGNX
| Q4 25 | $39.2M | $30.3M | ||
| Q3 25 | $36.1M | $29.7M | ||
| Q2 25 | $37.7M | $21.4M | ||
| Q1 25 | — | $89.0M | ||
| Q4 24 | $40.4M | $21.2M | ||
| Q3 24 | $40.5M | $24.2M | ||
| Q2 24 | $33.0M | $22.3M | ||
| Q1 24 | $39.6M | $15.6M |
净利润ALOTRGNX
| Q4 25 | $378.0K | $-67.1M | ||
| Q3 25 | $-1.2M | $-61.9M | ||
| Q2 25 | $-376.0K | $-70.9M | ||
| Q1 25 | — | $6.1M | ||
| Q4 24 | $240.0K | $-51.2M | ||
| Q3 24 | $-311.0K | $-59.6M | ||
| Q2 24 | $1.2M | $-53.0M | ||
| Q1 24 | $2.7M | $-63.3M |
毛利率ALOTRGNX
| Q4 25 | 36.2% | — | ||
| Q3 25 | 32.2% | — | ||
| Q2 25 | 33.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 33.9% | 70.2% | ||
| Q3 24 | 35.3% | 48.8% | ||
| Q2 24 | 36.3% | 52.5% | ||
| Q1 24 | 31.9% | 72.6% |
营业利润率ALOTRGNX
| Q4 25 | 3.3% | -190.0% | ||
| Q3 25 | -2.0% | -176.3% | ||
| Q2 25 | 1.5% | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | 3.1% | -242.1% | ||
| Q3 24 | 2.6% | -256.6% | ||
| Q2 24 | 4.1% | -251.3% | ||
| Q1 24 | 9.9% | -408.8% |
净利率ALOTRGNX
| Q4 25 | 1.0% | -221.3% | ||
| Q3 25 | -3.4% | -208.3% | ||
| Q2 25 | -1.0% | -331.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | 0.6% | -241.3% | ||
| Q3 24 | -0.8% | -246.3% | ||
| Q2 24 | 3.6% | -237.7% | ||
| Q1 24 | 6.8% | -405.4% |
每股收益（稀释后）ALOTRGNX
| Q4 25 | $0.05 | $-1.30 | ||
| Q3 25 | $-0.16 | $-1.20 | ||
| Q2 25 | $-0.05 | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | $0.03 | $-0.99 | ||
| Q3 24 | $-0.04 | $-1.17 | ||
| Q2 24 | $0.15 | $-1.05 | ||
| Q1 24 | $0.37 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $76.9M | $102.7M |
| 总资产 | $140.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALOTRGNX
| Q4 25 | $3.6M | $230.1M | ||
| Q3 25 | $3.9M | $274.2M | ||
| Q2 25 | $5.4M | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | $4.4M | $234.7M | ||
| Q3 24 | $4.8M | $255.5M | ||
| Q2 24 | $4.0M | $290.4M | ||
| Q1 24 | $4.5M | $338.7M |
股东权益ALOTRGNX
| Q4 25 | $76.9M | $102.7M | ||
| Q3 25 | $75.8M | $161.5M | ||
| Q2 25 | $76.6M | $213.7M | ||
| Q1 25 | — | $274.2M | ||
| Q4 24 | $92.2M | $259.7M | ||
| Q3 24 | $91.8M | $301.4M | ||
| Q2 24 | $91.2M | $348.3M | ||
| Q1 24 | $90.3M | $390.7M |
总资产ALOTRGNX
| Q4 25 | $140.8M | $453.0M | ||
| Q3 25 | $143.1M | $525.2M | ||
| Q2 25 | $150.3M | $581.0M | ||
| Q1 25 | — | $490.9M | ||
| Q4 24 | $166.5M | $466.0M | ||
| Q3 24 | $169.0M | $519.1M | ||
| Q2 24 | $126.6M | $569.4M | ||
| Q1 24 | $133.3M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $3.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 8.5% | -174.0% |
| 资本支出强度资本支出/营收 | 0.2% | 1.7% |
| 现金转化率经营现金流/净利润 | 9.05× | — |
| 过去12个月自由现金流最近4个季度 | $2.9M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ALOTRGNX
| Q4 25 | $3.4M | $-52.3M | ||
| Q3 25 | $249.0K | $-56.0M | ||
| Q2 25 | $4.4M | $-49.3M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | $-4.7M | $-31.6M | ||
| Q3 24 | $162.0K | $-40.5M | ||
| Q2 24 | $6.9M | $-45.5M | ||
| Q1 24 | $6.5M | $-55.5M |
自由现金流ALOTRGNX
| Q4 25 | $3.3M | $-52.8M | ||
| Q3 25 | $202.0K | $-56.5M | ||
| Q2 25 | $4.3M | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | $-5.0M | $-32.7M | ||
| Q3 24 | $-176.0K | $-40.9M | ||
| Q2 24 | $6.4M | $-46.0M | ||
| Q1 24 | $6.0M | $-56.0M |
自由现金流率ALOTRGNX
| Q4 25 | 8.5% | -174.0% | ||
| Q3 25 | 0.6% | -189.9% | ||
| Q2 25 | 11.5% | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | -12.4% | -154.2% | ||
| Q3 24 | -0.4% | -168.9% | ||
| Q2 24 | 19.5% | -206.2% | ||
| Q1 24 | 15.3% | -358.5% |
资本支出强度ALOTRGNX
| Q4 25 | 0.2% | 1.7% | ||
| Q3 25 | 0.1% | 1.7% | ||
| Q2 25 | 0.2% | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 0.6% | 5.1% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 1.5% | 2.1% | ||
| Q1 24 | 1.0% | 3.6% |
现金转化率ALOTRGNX
| Q4 25 | 9.05× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | -19.76× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.85× | — | ||
| Q1 24 | 2.38× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALOT
| Public Utilities Inventory Supplies | $20.6M | 53% |
| Hardware Products | $12.7M | 32% |
| Service And Other | $5.9M | 15% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
